Department of Surgery, Johns Hopkins Medical Institutions, Baltimore, MD, 21205, USA.
Department of Plastic and Reconstructive Surgery, Johns Hopkins Medical Institutions, Baltimore, MD, 21205, USA.
Breast Cancer Res Treat. 2021 Jul;188(1):101-106. doi: 10.1007/s10549-021-06177-9. Epub 2021 Mar 19.
PlasmaBlade® is a thermal dissection device that may allow for improved perfusion of the mastectomy flap by limiting thermal injury. In this study we aim to compare the mastectomy flap perfusion using PlasmaBlade® versus traditional electrocautery.
Patients undergoing bilateral mastectomy with immediate breast reconstruction were recruited. The right and left breasts of each patient were randomized to dissection with PlasmaBlade® or standard electrocautery. Randomization was performed using random sequences on the day of surgery and was blinded to the plastic surgeon. Mastectomy flap perfusion was assessed following completion of the mastectomy using intra-operative fluoroscopy and plastic surgeon review. Surgical site drainage and pain score were measured. Sign tests were employed to assess differences in perfusion and Wilcoxon paired test for the secondary outcomes.
Twenty patients were enrolled in the study with median age of 40.5 years and median BMI of 26 kg/m. In 18 patients (90%), perfusion was assessed to be better on the side of the PlasmaBlade® dissection. Median daily drainage over a 7-day period was 51 cc (IQR 35-61) on the PlasmaBlade® side and 44 cc (IQR 31-61) on the control side. Median pain score on the PlasmaBlade® side was 4.0 (IQR 2.3-5.9) and 4.4 (IQR 2.9-6) on the control side. No skin necrosis was noted in either groups.
Use of PlasmaBlade® appears to be a safe and reliable technique to perform mastectomy and breast reconstruction with equivalent outcomes to traditional electrocautery. Although, mastectomy skin flap perfusion was rated better intra-operatively for the PlasmaBlade® group, both cohorts had comparable outcomes. ClinicalTrials.gov Identifier: NCT03711916 Level of Evidence: I (Randomized trial).
PlasmaBlade® 是一种热分离设备,通过限制热损伤,可能改善乳房切除术皮瓣的灌注。本研究旨在比较使用 PlasmaBlade® 与传统电灼进行乳房切除术皮瓣的灌注。
招募了行双侧乳房切除术和即刻乳房重建的患者。每位患者的右侧和左侧乳房随机分为使用 PlasmaBlade® 或标准电灼进行解剖。手术当天使用随机序列进行随机分组,并对整形外科医生进行了盲法处理。在完成乳房切除术时使用术中荧光透视术和整形外科医生的评估来评估乳房切除术皮瓣的灌注。测量手术部位引流和疼痛评分。采用符号检验评估灌注差异,Wilcoxon 配对检验评估次要结局。
本研究纳入了 20 例患者,平均年龄为 40.5 岁,平均 BMI 为 26kg/m。在 18 例患者(90%)中,PlasmaBlade® 解剖侧的灌注被评估为更好。7 天期间每日平均引流量在 PlasmaBlade®侧为 51cc(IQR 35-61),在对照组为 44cc(IQR 31-61)。PlasmaBlade®侧的平均疼痛评分为 4.0(IQR 2.3-5.9),对照组为 4.4(IQR 2.9-6)。两组均未发生皮肤坏死。
使用 PlasmaBlade® 似乎是一种安全可靠的技术,可进行乳房切除术和乳房重建,其结果与传统电灼相当。尽管 PlasmaBlade®组术中乳房切除术皮瓣灌注评分更好,但两组的结果相当。ClinicalTrials.gov 标识符:NCT03711916 证据水平:I(随机试验)。